Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. 1981

J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes

We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7 +/- 8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular fibrillation and 21 of 29 with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. Side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
November 1983, The American journal of cardiology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
September 1978, American heart journal,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
February 1989, Journal of the American College of Cardiology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
February 1984, The American journal of cardiology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
June 1984, The American journal of cardiology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
March 1994, The Journal of thoracic and cardiovascular surgery,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
December 1983, The American journal of cardiology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
November 1989, British heart journal,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
June 1990, Journal of cardiovascular pharmacology,
J J Heger, and E N Prystowsky, and W M Jackman, and G V Naccarelli, and K A Warfel, and R L Rinkenberger, and D P Zipes
June 2000, The Canadian journal of cardiology,
Copied contents to your clipboard!